1. HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients
- Author
-
Eun Seok Kang, Hye Jin Wang, Eun Yeong Choe, Hyun Chul Lee, Kyu Ha Huh, Yu Seun Kim, Myoung Soo Kim, Bong Soo Cha, Yongin Cho, Chul Woo Ahn, and Obin Kwon
- Subjects
Adult ,Blood Glucose ,Male ,medicine.medical_specialty ,Statin ,Indoles ,endocrine system diseases ,medicine.drug_class ,Atorvastatin ,Gastroenterology ,Diabetes Complications ,Fatty Acids, Monounsaturated ,Diabetes mellitus ,Internal medicine ,Diabetes Mellitus ,Medicine ,Humans ,Pyrroles ,cardiovascular diseases ,Renal Insufficiency ,Fluvastatin ,Dyslipidemias ,Transplantation ,business.industry ,Anticholesteremic Agents ,Incidence ,Hazard ratio ,nutritional and metabolic diseases ,Fasting ,Middle Aged ,medicine.disease ,Impaired fasting glucose ,Kidney Transplantation ,Heptanoic Acids ,Hyperglycemia ,lipids (amino acids, peptides, and proteins) ,Female ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business ,Dyslipidemia ,Immunosuppressive Agents ,medicine.drug ,Follow-Up Studies ,Glomerular Filtration Rate - Abstract
BACKGROUND Dysglycemia and dyslipidemia are important metabolic complications of organ transplantation. Statins are widely used to control dyslipidemia; however, long-term use of statins is related to diabetes mellitus (DM) and impaired fasting glucose (IFG). The aim of this study was to evaluate the influence of statins on the development of dysglycemia (IFG and/or DM) in renal allograft recipients. METHODS A total of 394 patients without previously known DM or IFG who underwent kidney transplantation were enrolled. Patients were grouped into the two groups according to the use of statin (control, n=149; statin, n=245). The major statins used were fluvastatin (80 mg/d, n=134) and atorvastatin (20 mg/d, n=111). We compared the incidence of IFG or DM during the follow-up period. RESULTS The incidence of IFG was higher in the statin group than that in the control group (28.6% vs. 8.7%, P
- Published
- 2013